ZENdocrinology

10/01/2025

08/01/2025

Hopefully the shortages will cease

Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, said Monday it was investing 8.5 billion kroner ($1.2 billion) to build a new factory in Denmark to produce drugs against rare diseases.

27/12/2024

Good to better understand your CGMS readings.

⭐PATIENT INFORMATION⭐📌Continuous Glucose Monitoring and Nutrition

Understanding CGM readings and maximizing their benefits.

Read & Share➡doi.org/10.2337/cd24-pe03
PDF Available➡diabetesjournals.org/clinical/article-pdf/42/3/463/775168/diaclincd24pe03.pdf



American Diabetes Association American Diabetes Association – DiabetesPro

27/12/2024

From Helio via Cleveland Clinic:

"Several GLP-1 Receptor Agonists May Be Associated With Reduced Risk For Dementia Diagnosis In Older Adults With Diabetes, Study Indicates
Healio (12/24, Rhoades) reported, “Several glucagon-like peptide-1, or GLP-1, receptor agonists may be associated with reduced risk for a dementia diagnosis in older adults with diabetes, according to a recent study from Epic Research.” Investigators came to this conclusion after conducting a “study — which did not undergo peer review” – assessing “the likelihood of a dementia diagnosis within 5 years of starting a GLP-1 receptor agonist or another diabetes medication using a cohort of 549,822 patients aged 60 years or older with type 2 diabetes.”

Link to original article:

25/11/2023

This is an "SGL2 Inhibitor" like Jardiance, Farxiga, and Invoking.
If you have a high pharmacy deductible, or issues with the Medicare Part D gap, or a very high copayment/coinsurance - you might consider requesting your provider prescribe this SGL2I through Cost Plus Drugs as the cash price below 50 dollars a month.

📢 We now carry Brenzavvy™ (bexagliflozin) on costplusdrugs.com thanks to TheracosBio!

https://costplusdrugs.com/medications/brenzavvy-20mg

A 30-day supply of the newest SGLT2 inhibitor on the market is available for $47.85 + shipping. Visit brenzavvy.com for full details on the medication.

Ready to get your diabetes medication on Cost Plus Drugs?

➡️ Sign up today at costplusdrugs.com/create-account/
No membership fees.
No insurance required.

11/04/2023

If you are paying out of pocket, have a high deductible , etc for an SGL2I class of medication Cost Plus medications just added Invoking / Invokamet to their program.

Mark Cuban’s Cost Plus Drug Company recently added SGLT-2 inhibitor Invokana to its list of available medications. The company, which uses an innovative business model to provide drugs at heavily discounted prices, could potentially offer financial relief to millions of Americans.

24/03/2023

https://diatribe.org/updated-medicare-insulin-options-2023?omhide=true

If you are using Medicare Part D - there is a new open enrollment allowing you to change your plan - due to the changes made in insulin costs.

The Centers for Medicare and Medicaid Services has created a Special Enrollment Period for people with insulin to change their Part D coverage and ensure they are not paying more than $35 each month for the insulin product.

06/03/2023

Having a hard time getting your diabetes medication? It is not just due to shortages. If you use an independent pharmacy you must read this ...

Some independent pharmacies are losing money on the pricey — and popular — drug.

03/08/2022

People with diabetic retinopathy who took the cholesterol-lowering drug fenofibrate were less likely to progress to vision-threatening forms of the disease, in a large database study.

31/05/2022

The Freestyle Libre 3, the world's smallest continuous glucose monitor, offering several improvements and updates from the Libre 2, has received FDA approval.

15/04/2022

The 25th International Thyroid Cancer Survivors' Virtual Conference will be held September 16-18. Mark your calendars! To register: www.ThyCa.org/conference

04/03/2022

Launching to market in 2024, Civica Rx aims to make insulin available for no more than $30 per vial, regardless of insurance status.